RTW Biotech OpportunitiesLSE:RTW +2.68%36 ROE % is 78.85% as of Dec. 2025, which is 221% above its 10-year median of 24.53. GuruFocus rates LSE:RTW with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,615 Asset Management companies, RTW Biotech Opportunities ranks better than 93.07% on this metric.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, RTW Biotech Opportunities's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities ROE % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's ROE % distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
RTW Biotech Opportunities (LSE:RTW) has a ROE % of 78.85% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on RTW Biotech Opportunities and its competitors. This is 221% above median its historical median of 24.53. According to the industry distribution chart, RTW Biotech Opportunities ranks #112 out of 1615 companies in the Asset Management industry, placing it in the top 6.9%.
Is RTW Biotech Opportunities' ROE % too high?
RTW Biotech Opportunities' current ROE % of 78.85% is 221% above median its 10-year median of 24.53. The Asset Management industry median ROE % is 6.35. RTW Biotech Opportunities' value of 78.85% is 1141.7% above this industry median. Based on the distribution chart, RTW Biotech Opportunities ranks #112 out of 1615 companies in the Asset Management industry, which is in the top quartile — a strong position relative to peers. Overall, RTW Biotech Opportunities has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' ROE % compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #112 out of 1615 companies for ROE %. This places RTW Biotech Opportunities in the top 7% of its industry — outperforming the majority of peers. The industry median ROE % is 6.35. RTW Biotech Opportunities' value of 78.85% is 1141.7% above this benchmark. While the company's 10-year median is 24.53 vs. the industry median of 6.35, RTW Biotech Opportunities has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for an Asset Management company?
The median ROE % among Asset Management companies is 6.35, based on 1,615 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RTW Biotech Opportunities's current ROE % of 78.85% is 1141.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on RTW Biotech Opportunities and its competitors. For the Asset Management industry, the median ROE % is 6.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current ROE % is 78.85%, which is 221% above median its own 10-year median of 24.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current ROE % of 78.85%. The current ROE % is 78.85%, which is 221% above median its 10-year median of 24.53 and 1141.7% above the Asset Management industry median of 6.35. RTW Biotech Opportunities' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current ROE % is 78.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
36GF Score
Get the complete analysis for LSE:RTW
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
